Wire flash
Novo Nordisk: Oral Obesity Drug Capacity to Serve 10x More Patients by 2030
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Novo Nordisk has announced plans to significantly expand its production capacity by 2030 to serve ten times the number of obese patients using its oral GLP-1 medications. The Danish pharmaceutical company also set a long-term sales target for its pipeline, aiming to achieve over 150 billion Danish kroner in revenue by 2035. The announcement, reported by tradealpha, underscores the company's aggressive growth strategy in the obesity treatment market, driven by the high demand for its oral GLP-1 therapies.
Source report
Copenhagen – Novo Nordisk has announced plans to significantly expand its production capacity by 2030, aiming to serve up to ten times the number of obese patients using oral GLP-1 treatments.
The company also set a pipeline sales target of over 150 billion Danish kroner by 2035.
Source
domesticNeutral / independent
Part of this Story
Novo Nordisk shares fall 5.4% as 2030 pipeline plan fails to impress investors